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Abstract
Background: Sclerostin is a paracrine acting factor, which is expressed in the osteocytes and articular
chondrocytes. Sclerostin decreases the osteoblast-related bone formation through the inhibition of the Wnt/β-
catenin pathway. Osteocytes also express the Calcium sensing receptor which is a target for cinacalcet. The aim of
this study was to assess the influence of six-month cinacalcet treatment on plasma sclerostin concentration in
hemodialysed patients with secondary hyperparathyroidism (sHPT).
Methods: In 58 hemodialysed patients with sHPT (PTH > 300 pg/ml) plasma sclerostin and serum PTH, calcium and
phosphate concentrations were assessed before the first dose of cinacalcet and after 3 and 6 months of treatment.
Results: Serum PTH concentration decreased after 3 and 6 month of treatment from 1138 (931–1345) pg/ml to 772
(551–992) pg/ml and to 635 (430–839) pg/ml, respectively. Mean serum calcium and phosphate concentrations
remained stable. Plasma sclerostin concentration increased after 3 and 6 months of treatment from 1.66 (1.35–1.96)
ng/ml, to 1.77 (1.43–2.12) ng/ml and to 1.87 (1.50–2.25) ng/ml, respectively. In 42 patients with cinacalcet induced
serum PTH decrease plasma sclerostin concentration increased after 3 and 6 months of treatment from 1.51 (1.19–1.
84) ng/ml to 1.59 (1.29–1.89) ng/ml and to 1.75 (1.42–2.01) ng/ml, respectively. Contrary, in the 16 patients without
cinacalcet induced serum PTH decrease plasma sclerostin concentration was stable. Plasma sclerostin
concentrations correlated inversely with serum PTH concentrations at the baseline and also after 6 months of
treatment.
Conclusions: 1. In hemodialysed patients with secondary hyperparathyroidism treatment with cinacalcet increases
plasma sclerostin concentration 2. This effect seems to be related to decrease of serum PTH concentration.
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Background
Sclerostin is a 22 kDa protein which acts as a soluble in-
hibitor of the canonical Wnt/β-catenin pathway [1]. It is
synthetized mostly by osteocytes as a product of SOST
gene. Recently SOST expression has been described not
only in the bone and cartilage but also in calcifying
arterial tissue and heart valves [2–4], thus linking scler-
ostin with the vascular calcification. Deletion, or attenu-
ation of SOST gene at the transcriptional level lead to
the development of sclerostosis, or van Buchem’s
disease – both of these morbidities lead to the in-
creased bone mass [5, 6].
There is growing evidence that the effects of parathy-
roid hormone (PTH) on bone may be, at least partially,
mediated by sclerostin expression. Administration of ex-
ogenous PTH leads to the decrease of sclerostin expres-
sion in osteocytes of mice [7]. Also in humans an
inverse relation between plasma sclerostin and serum
PTH concentrations has been found [8].
Chronic kidney disease is associated with the develop-
ment of secondary hyperparathyroidism (sHPT) and
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concomitant CKD-MBD (chronic kidney disease-mineral
and bone disorders). This leads to the increased inci-
dence of bone fractures, vascular calcification and thus
greater morbidity and mortality in patients with CKD.
Plasma concentration of sclerostin tends to increase
across the stages of CKD [9, 10] and is significantly ele-
vated in maintenance hemodialysis patients [11]. It is
important to stress that it is yet unknown if higher
plasma sclerostin is beneficial or harmful in this group
of patients. The studies conducted so far considering the
influence of sclerostin in the development of arterial cal-
cifications (and atherosclerosis) [12–15] as well as the
cardiovascular and total mortality [16–19] yielded con-
flicting results. There are some studies however linking
the increased plasma sclerostin concentrations in CKD
with the development of renal osteodystrophy [20].
Calcium sensing receptor (CaSR) is a seven-
transmembrane G-protein-coupled receptor, which
was classically seen as a mere modulator of the para-
thyroid hormone (PTH) secretion in the parathyroid
glands in response to serum calcium concentration
changes [20]. Recently, the expression of CaSR has
been documented outside the parathyroid glands,
among others in bone [21, 22].
Cinacalcet is a calcimimetic. Such compounds bind to
the CaSR leading to its allosteric modulation which results
in the increased receptor’s sensitivity to serum calcium
[20]. This leads to decreased PTH production in the para-
thyroid glands and usually concomitant decrease of serum
calcium and phosphate concentrations [23–25].
There are more and more lines of evidence suggesting
the importance of sclerostin in the etiopathogenesis of
the increased morbidity and mortality of maintenance
hemodialysis patients. Moreover, there are at least two
potential mechanisms of the influence of cinacalcet on
plasma sclerostin concentration (direct – via the CaSR
activation, and indirect – via the serum PTH concentra-
tion decrease). Taking the aforementioned facts into
consideration it seemed rational to study the influence
of 6-month cinacalcet regimen on plasma sclerostin con-
centrations in chronic hemodialysis patients with sHPT.
Methods
Seventy one adult, chronic hemodialysis patients (40
males, 31 females) with sHPT (serum PTH concentra-
tion >300 pg/ml) were enrolled in this prospective,
open-label, single arm study. Mean age of patients
was 53.3 ± 14.8 years, median time of renal replace-
ment therapy was 32 ± 28 months. Exclusion criteria
were: age below 18 years, severe liver insufficiency,
oversensitivity to any of the study drug compounds,
high probability of non-compliance and suspected
short life expectancy on renal replacement therapy.
All patients have been dialyzed using bicarbonate di-
alysate with dialysate ionized calcium concentration of
1.25 mEq/l in all time-points of the study.
All enrolled patients were treated with cinacalcet. Ini-
tial dose was 30 mg once daily and was modified, if it
was needed, every 4 weeks depending on the serum
PTH concentration. The target of treatment was to de-
crease serum PTH concentration to 150–300 pg/ml.
Maximal allowed dose of cinacalcet was 120 mg daily.
All patients were cinacalcet naïve and no other
parathyroid-suppressive treatment (besides alfacalcidol)
has been used during enrollment or previously.
The doses of calcium carbonate and alfacalcidol
were flexible in order to avoid hypocalcemia and
hypophosphatemia related to the cinacalcet treatment.
In some patients aluminum hydroxide was used as a
temporary “rescue” therapy in patients with severe
hyperphosphatemia.
In every patient plasma sclerostin concentration and
serum PTH, calcium, and phosphate concentrations
were assessed before the first dose of cinacalcet and then
after 3 and 6 months of treatment. Blood samples were
collected directly before hemodialysis procedure in the
middle of the week. After collection blood samples were
centrifuged, serum was aliquoted in 1 ml test-tubes and
frozen in -70 °C until assay. Serum PTH concentration
was assessed using electrochemiluminescence (ECL)
technique (Roche, Mannheim, Germany) and plasma
sclerostin concentration was assessed with an ELISA
(Teco Medical, San Diego, CA, USA). Intra-assay coeffi-
cient of variation for sclerostin was 3.7–4.0 %. Inter-
assay coefficient of variation was 4.3–4.8 %.
Serum calcium and phosphate concentration was
assessed using the standard procedures of the hospital’s
central laboratory (Beckman-Coulter DxC 600 analyzer).
Statistical analyses were performed using the Statistica
10.0 PL software (StatSoft Polska, Cracow, Poland).
Shapiro-Wilk test was used to test the variables distribu-
tion. Repeated measures ANOVA test with Bonferroni’s
correction for multiple comparisons was used to assess
the changes of variables over time. One way ANOVA
was used to assess the differences between groups and
chi2 test to assess the differences in qualitative variables.
Correlation coefficients were calculated according to the
Spearman’s rank correlation method. Additionally, back-
wards multiple regression models were built (with the
plasma sclerostin concentration as a dependent variable
and the variables that reached a level of dependence p <
0.2 in the univariate regression analyses as independent
factors) in each time-point of the study.
Furthermore, similar multiple regression models were
built involving only the patients in whom treatment with
cinacalcet caused a significant (>10 %) serum PTH con-
centration decrease.
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Results are shown as means with 95 % confidence
index (CI), or as means with standard deviation, alterna-
tively as median values with interquartile range (IQR)
for variables with skewed distribution. Differences were
considered significant when p < 0.05.
The study protocol, adherent to Declaration of
Helsinki, was approved by the Medical University of
Silesia Bioethics Committee (KNW/0022/KB1/56/I/10 -
21.09.2010) and all patients gave their written informed
consent for participation in the study.
Results
From 71 enrolled patients, 58 (35 males, 23 females,
mean age 53.8 ± 14.9 years) completed the study. Among
13 patients ruled out of the study 4 people died, 2 re-
ceived kidney allograft, 2 patients discontinued the study
because of permanent decrease of serum PTH concen-
tration below 150 pg/ml, 2 underwent parathyroidec-
tomy, one patient refused to continue the treatment due
to paresthesia, one patient withdrew the consent for the
study and one moved out and was lost to follow-up.
The mean doses of cinacalcet after 3 and 6 months of
treatment were 42 ± 17 mg and 51 ± 23 mg, respectively.
The dosing of calcium carbonate and alfacalcidol was
flexible in order to avoid hypocalcemia and hypopho-
sphatemia related to cinacalcet treatment. The mean
daily dose of alfacalcidol increased (p for trend = 0.044)
from 0.26 μg (0.17–0.36 μg) at the baseline, to 0.33 μg
(0.20–0.45 μg) after 3 months and to 0.39 μg (0.25–
0.52 μg) after 6 months, but there were no significant
differences found between the doses after correction for
multiple comparisons. The percentage of patients treated
with alfacalcidol did not change significantly [30 (52 %)
at the baseline, 34 (54 %) after 3 month of treatment
and 40 (69 %) after 6 months; p for trend = 0.06). More-
over, there was a significant (p for trend = 0.01) decrease
in the mean dose of aluminum hydroxide (Alusal) from
385 mg/day (170–410 mg/day) at the baseline, to
310 mg/day (80-540 mg/day); p = 0.15 after 3 months,
and to 180 mg/day (15–350 mg/day); p = 0.03, after
6 months of treatment, but the change in the number
of patients treated with aluminum hydroxide was not
significant [12 (21 %), 8 (14 %) and 5 (8 %) patients,
respectively; p for trend = 0.06)]. The mean dose of
calcium carbonate (p for trend = 0.055) and the num-
ber of patients (p for trend = 0.71) treated with this
drug remained stable. The mean dose was 3.49 g/day
(2.68–4.30 g/day) at the baseline, 3.84 g/day (2.95–
4.72 g/day); p = 0.14 after 3 months of treatment
3.88 g/day (3.04–4.72 g/day); p = 0.16 after 6 months
of treatment. The number of patients treated with
calcium carbonate was 53 (91 %), 55 (95 %) and 54
(93 %), respectively.
In patients who completed the study, cinacalcet treat-
ment caused significant decrease of serum PTH concen-
tration after 3 and 6 months of treatment (Table 1).
Serum PTH concentration decreased in 42 out of 58 pa-
tients (72 %), in the remaining 28 % it increased or
remained stable (change of serum PTH < 10 %). The
mean decrease of serum PTH concentration after 3 and
6 months of treatment was 32.2 % and 44.2 %
respectively.
There were no significant in the mean serum calcium
and phosphate concentration during cinacalcet treat-
ment (Table 1).
Mean plasma sclerostin concentration increased sig-
nificantly after 6 months of treatment with cinacalcet
(Fig. 1).
As it was mentioned above in 42 patients serum
PTH concentration decreased after treatment with
cinacalcet. In this sub-group plasma sclerostin con-
centrations also significantly increased. Contrary, in
the patients with no serum concentration of PTH de-
crease, plasma sclerostin concentrations remained
stable, but were markedly higher (p = 0.045) in com-
parison with the patients in whom serum PTH con-
centration decreased (Table 1).
A significant negative correlation between plasma
sclerostin and serum PTH concentrations was found
at the baseline and after 6 months of treatment










p vs. baseline (with Bonferroni’s correction)
3 months 6 months
Serum PTH concentration [pg/ml] 1138 (931–1345) 772 (551–992) 635 (430–839) <0.0001 0.0002 <0.0001
Serum calcium concentration [mmol/l] 2.15 (2.07–2.22) 2.11 (2.04–2.17) 2.08 (2–2.15) 0.15 0.86 0.45
Serum phosphate concentration [mmol/l] 2.02 (1.87–2.18) 1.97 (1.81–2.14) 1.90 (1.74–2.05) 0.11 1 0.33
Plasma sclerostin concentration patients
with PTH decrease [ng/ml]; (n = 42)
1.51 (1.19–1.84) 1.59 (1.29–1.89) 1.75 (1.42–2.01) 0.01 0.74 0.03
Plasma sclerostin concentration patients
without PTH decrease [ng/ml]; (n = 16)
2.09 (1.32–2.85) 2.33 (1.27–3.40) 2.30 (1.16–3.45) 0.34 0.60 1
PTH parathyroid hormone
Kuczera et al. BMC Nephrology  (2016) 17:176 Page 3 of 7
(borderline significance after 3 months) – Table 2.
Moreover, there was a significant positive correlation
between plasma sclerostin and serum phosphate con-
centrations at the baseline and after 6 months of
treatment (borderline significance after 3 months of
treatment) – Table 2. There was no significant
correlation between plasma sclerostin and serum
calcium concentrations or the dose of cinacalcet
(Table 2).
The magnitude of plasma sclerostin concentration in-
crease was significantly correlated with the change of
serum calcium concentration after both 3 and 6 months
of treatment, but no correlations were found between
the change of plasma sclerostin and the changes of
serum concentrations of PTH, phosphate, nor the dose
of cinacalcet (Table 3).
To further emphasize the relations between the above-
mentioned variables, backward multiple regression
Fig. 1 Plasma slerostin concentrations during cinacalcet treatment
Table 2 The correlation coefficients between plasma sclerostin concentrations and the serum concentrations of: calcium,
phosphate, PTH, and the dose of cinacalcet
Plasma sclerostin [ng/ml]
baseline 3 months 6 months
serum calcium [mmol/l] baseline R = -0.06; p = 0.67
3 months R = -0.06; p = 0.67
6 months R = 0.19; p = 0.18
serum phosphate [mmol/l] baseline R = 0.43; p = 0.001
3 months R = 0.24; p = 0.08
6 months R = -0.34; p = 0.01
serum PTH [ng/ml] baseline R = -0.27; p = 0.046
3 months R = -0.25; p = 0.07
6 months R = -0.40; p = 0.003
cinacalcet dose [mg] baseline n/a
3 months R = 0.05; p = 0.72
6 months R = -0.03; p = 0.84
PTH parathyroid hormone
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models were calculated. The results of the multiple
regression analyses were similar to those obtained in
univariate correlation analyses. Plasma sclerostin con-
centration at the baseline was explained by the serum
concentrations of phosphate (rpartial = 0.50; p = 0.0002)
and PTH (inversely: rpartial = -0.38; p = 0.005).
After 3 months of treatment plasma sclerostin concen-
tration was explained by the serum concentrations of
phosphate (rpartial = 0.35; p = 0.01) and not PTH (border-
line significance: rpartial = -0.27; p = 0.06). Serum calcium
concentration and cinacalcet dose did not retain in the
regression model.
After 6 months of treatment plasma sclerostin concen-
tration was explained by the serum concentrations of
phosphate (rpartial = 0.40; p = 0.004) and PTH (inversely:
rpartial = -0.28; p = 0.05). Serum calcium concentration
and cinacalcet dose did not retain in the regression
model.
Additionally, we have repeated the abovementioned
calculations involving only the patients with significant
decrease of serum PTH concentration during the cina-
calcet treatment.
After 3 months of treatment plasma sclerostin con-
centration (in patients with PTH decrease) was ex-
plained by the serum concentrations of PTH
(inversely: rpartial = -0.43; p = 0.008) and the dose of
cinacalcet (r = 0.30; p = 0.04) and not phosphate, nor
calcium (did not retain in the regression model).
After 6 months of treatment plasma sclerostin con-
centration (in patients with PTH decrease) was ex-
plained by the serum concentrations of phosphate
(rpartial = 0.28; p = 0.01) and PTH (inversely: rpartial = -0.49;
p = 0.001) and not cinacalct dose (rpartial = 0.45; p = 0.15).
Serum calcium concentration did not retain in the regres-
sion model.
Furthermore, we tested if plasma sclerostin was associ-
ated with the magnitude of PTH decrease. In a multiple
regression model the change of serum PTH was not
significantly inversely explained by sclerostin concentra-
tion (rpartial = -0.23; p = 0.1), still it was the only variable
related enough to be retained in the regression model
(neither cinacalcet dose, nor the concentrations of cal-
cium and phosphate retained).
Discussion
In the current clinical study a significant increase of
plasma sclerostin concentration in chronic hemodialysis
patients with sHPT after six-months treatment with
cinacalcet was observed (Fig. 1). Plasma sclerostin con-
centration seems to be related with serum PTH
concentration.
As far as we are aware this is the first study describing
the impact of cinacalcet treatment on plasma sclerostin
concentration. As it was mentioned before we have
found a relation between plasma sclerostin and serum
PTH concentrations. Similar results have been obtained
by other authors [11, 12]. Also the association between
plasma concentration of sclerostin and serum phosphate
have been previously described [10].
Interestingly, we have found that the increase of
plasma sclerostin concentration was only observed in
patients with the decrease of serum PTH concentration
(n = 42), while in the patients with no serum PTH con-
centration decrease i.e. “resistant” to cinacalcet treat-
ment plasma sclerostin was stable. These results might
suggest that the increase of plasma sclerostin in our
group of patients was rather secondary to the decrease
of serum PTH concentration than to a direct stimulation
of osteoblast CaSR in bone; however the latter cannot be
excluded based solely on the current study results.
Moreover, we have observed that in patients with
serum PTH concentration decrease caused by the cina-
calcet treatment, serum PTH concentration was the
strongest predictor of plasma sclerostin concentration
what additionally strengthens our conclusions.
Table 3 Correlation coefficients between the changes of plasma sclerostin concentration and changes of serum calcium, phosphate
and PTH concentration, as well as the dose of cinacalcet after 3 and 6 months of treatment
Change of plasma sclerostin [ng/ml]
0–3 months 0–6 months
change of serum calcium [mmol/l] 0–3 months R = -0.31; p = 0.03
0–6 months R = -0.37; p = 0.009
change of serum phosphate [mmol/l] 0–3 months R = 0.01; p = 0.96
0–6 months R = -0.06; p = 0.67
change of serum PTH [pg/ml] 0–3 months R = -0.07; p = 0.64
0–6 months R = -0.18; p = 0.21
cinacalcet dose [mg] 0–3 months R = -0.13; p = 0.36
0–6 months R = -0.15; p = 0.29
PTH parathyroid hormone
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The clinical significance of this finding is yet not
known as there are conflicting results of clinical trials
concerning the influence of sclerostin on vascular calcifi-
cations and mortality [12–19]. It is possible that scleros-
tin is expressed in the calcifying arterial wall in order to
inhibit vascular calcification and the measured increase
is an effect of a spill-over from the vascular wall. This is
probable in the light of the secondary analyses of AD-
VANCE Study [26], in which a slower coronary arteries
calcification was observed under cinacalcet regimen in
comparison with the conventional treatment. It is tempt-
ing to hypothesize that this might be caused by greater
sclerostin expression and thus explain our findings. On
the other hand in the paper by Quershi et al [27], the
authors conclude, that plasma sclerostin levels predict
the magnitude of vascular calcification, still it is yet un-
known if the increased concentrations of sclerostin are
the cause, or effect of the increased calcification of the
vasculature.
Interestingly, Behets et al. [28] found that treatment
with cinacalcet reduced the elevated bone formation
rate/tissue area in maintenance HD patients. If this ef-
fect could be mediated by the increased sclerostin ex-
pression is so far unknown, but it could be an elegant
confirmation of current study results.
All of the abovementioned studies, sometimes yielding
conflicting results, additionally underline the necessity of
conduction another clinical studies regarding the influ-
ence of sHPT treatment on sclerostin and other markers
of bone metabolism.
Another phenomenon which needs further investiga-
tion is if plasma sclerostin concentration could be the
predictive factor of the resistance to cinacalcet treat-
ment. Such a conclusion seems to emerge from the
current study results, but it did not reach the sufficient
statistical significance in the multiple regression analysis,
thus larger group of patients is needed to confirm this
hypothesis.
Our study has some limitations. The most important is
the lack of placebo controlled patients. Nevertheless, as
cinacalcet is nowadays so commonly used in the treat-
ment of sHPT, conducting a placebo-controlled study with
this agent rises some significant methodological and eth-
ical issues. Furthermore, it might be hypothesized that the
increase of plasma sclerostin concentration reported in
the current study is merely due to the seasonal change as
it has been reported by Dawson-Hughes et al [29]. This is
however unlikely, as our patients were gradually enrolled
into the study in a 13-month period, what precludes the
impact of seasonal change. Moreover, the above-
mentioned study was conducted in healthy subjects and
there is no such data available in the maintenance
hemodialysis patients population, in which the baseline
sclerostin concentrations are already increased [11].
Summing up, we have found that treatment with cina-
calcet increases plasma sclerostin concentration in
hemodialysed patients with secondary hyperparathyroid-
ism. It is plausible to assume that such an increase is ra-
ther caused by the cinacalcet-related serum PTH
decrease than by the direct stimulation of CaSR in bone.
Conclusions
1. In hemodialysed patients with secondary hyperpara-
thyroidism treatment with cinacalcet increases plasma
sclerostin concentration 2. This effect seems to be re-
lated to decrease of serum PTH concentration.
Abbreviations
CaSR: Calcium sensing receptor; CKD: Chronic kidney disease; CKD-
MBD: Chronic kidney disease-mineral and bone disorders; PTH: Parathyroid




The study was funded by the Medical University of Silesia, Poland – contract
number: KNW-1-120/N/6/K.
Availability of data and materials
The datasets generated during and/or analysed during the current study are
not publicly available due to the fact that individual privacy could be
compromised, but are available from the corresponding author on
reasonable request.
Authors’ contributions
PK has been responsible for the patients’ enrolment, samples collection and
storage, data interpretation, statistical analyses and the writing of the
manuscript. MA has been responsible for the data interpretation, statistical
analyses, writing and correction of the manuscript. AW was the study
originator and has been responsible for funding, the writing and correction
of manuscript and has been the study supervisor. All authors have read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study protocol, adherent to Declaration of Helsinki, was approved by the
Medical University of Silesia Bioethics Committee (KNW/0022/KB1/56/I/10 -
21.09.2010) and all patients gave their written informed consent for
participation in the study.
Received: 2 July 2016 Accepted: 8 November 2016
References
1. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt
signaling. J Clin Invest. 2006;116:1202–9.
2. Zhu D, Mackenzie NC, Millan JL, et al. The appearance and modulation of
osteocyte marker expression during calcification of vascular smooth muscle
cells. PLoS ONE. doi: 10.1371/journal.pone.0019595
3. Koos R, Brandenburg V, Mahnken AH, et al. Sclerostin as a potential novel
biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart
Valve Dis. 2013;22:317–25.
4. Kramann R, Brandenburg VM, Schurgers LJ, et al. Novel insights into
osteogenesis and matrix remodelling associated with calcific uraemic
arteriolopathy. Nephrol Dial Transplant. 2013;28:856–68.
Kuczera et al. BMC Nephrology  (2016) 17:176 Page 6 of 7
5. Brunkow ME, Gardner JC, Van NJ, et al. Bone dysplasia sclerosteosis results
from loss of the SOST gene product, a novel cystine knot-containing
protein. Am J Hum Genet. 2001;68:577–89.
6. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion
downstream of the SOST gene in patients with van Buchem disease. J Med
Genet. 2002;39:91–7.
7. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid
hormone in mice reduces expression of sclerostin by osteocytes: a
novel mechanism for hormonal control of osteoblastogenesis.
Endocrinology. 2005;146:4577–83.
8. Mirza FS, Padhi ID, Raisz LG, et al. Serum sclerostin levels negatively
correlate with parathyroid hormone levels and free estrogen index in
postmenopausal women. J Clin Endocrinol Metab. 2010;95:1991–7.
9. Claes KJ, Viaene L, Heye S, et al. Sclerostin: another vascular calcification
inhibitor? J Clin Endocrinol Metab. 2013;98:3221–8.
10. Pelletier S, Dubourg L, Carlier MC, et al. The relation between renal function
and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol.
2013;8:819–23.
11. Delanaye P, Krzesinski JM, Warling X, et al. Clinical and biological
determinants of sclerostin plasma concentration in hemodialysis patients.
Nephron Clin Pract. 2014;128:127–34.
12. Yang CY, Chang ZF, Chau YP, et al. Circulating Wnt/β-catenin signalling
inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant.
2015;30:1356–63.
13. Kirkpantur A, Balci M, Turkvatan A, et al. Independent association between
serum sclerostin levels and carotid artery atherosclerosis in prevalent
haemodialysis patients. Clin Kidney J. 2015;8:737–43.
14. Kirkpantur A, Balci M, Turkvatan A, et al. Serum sclerostin levels,
arteriovenous fistula calcification and 2-years all-cause mortality in prevalent
hemodialysis patients Nefrologia. doi: 10.1016/j.nefro.2015.07.006.
15. Kim KM, Lim S, Moon JH, et al. Lower uncarboxylated osteocalcin and
higher sclerostin levels are significantly associated with coronary artery
disease. Bone. 2015;83:178–83.
16. Kanbay M, Siriopol D, Saglam M, et al. Serum sclerostin and adverse
outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol
Metab. 2014;99:E1854–61.
17. Gonçalves FL, Elias RM, dos Reis LM, et al. Serum sclerostin is an
independent predictor of mortality in hemodialysis patients. BMC Nephrol.
2014;15:190.
18. Drechsler C, Evenepoel P, Vervloet MG, et al. High levels of circulating
sclerostin are associated with better cardiovascular survival in incident
dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant.
2015;30:288–93.
19. Viaene L, Behets GJ, Claes K, et al. Sclerostin: another bone-related protein
related to all-cause mortality in haemodialysis? Nephrol Dial Transplant.
2013;28:3024–30.
20. Moysés RM, Schiavi SC. Sclerostin, Osteocytes, and Chronic Kidney Disease -
Mineral Bone Disorder. Semin Dial. 2015;28:578–86.
21. Harrington PE, Fotsch C. Calcium sensing receptor activators, calcimimetics.
Curr Med Chem. 2007;14:3027–34.
22. Marie PJ. The calcium-sensing receptor in bone cells: a potential therapeutic
target in osteoporosis. Bone. 2010;46:571–6.
23. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized
study to evaluate the effects of cinacalcet plus low-dose vitamin D on
vascular calcification in patients on hemodialysis. Nephrol Dial Transplant.
2011;26:1327–39.
24. Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-
dose vitamin D improves treatment of secondary hyperparathyroidism in
dialysis patients compared with vitamin D alone: the ACHIEVE study results.
Clin J Am Soc Nephrol. 2008;3:1718–25.
25. Kuczera P, Adamczak M, Więcek A. Safety and efficiency of treatment with
cinacalcet of haemodialysed patients with chronic kidney disease and
secondary hyperparathyroidism. Endokrynol Pol. 2013;64:176–81.
26. Bellasi A, Reiner M, Pétavy F, et al. Presence of valvular calcification predicts
the response to cinacalcet: data from the ADVANCE study. J Heart Valve Dis.
2013;22:391–9.
27. Qureshi AR, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A,
Lindholm B, Söderberg M, Wennberg L, Nordfors L, Ripsweden J, Barany P,
Stenvinkel P. Increased circulating sclerostin levels in end-stage renal
disease predict biopsy-verified vascular medial calcification and coronary
artery calcification. Kidney Int. 2015;88:1356–64.
28. Behets GJ, Spasovski G, Sterling LR, Goodman WG, Spiegel DM, De Broe ME,
D'Haese PC. Bone histomorphometry before and after long-term treatment
with cinacalcet in dialysis patients with secondary hyperparathyroidism.
Kidney Int. 2015;87:846–56.
29. Dawson-Hughes B, Harris SS, Ceglia L, Palermo NJ. Serum sclerostin levels
vary with season. J Clin Endocrinol Metab. 2014;99:149–52.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kuczera et al. BMC Nephrology  (2016) 17:176 Page 7 of 7
